Skip to main content
Top
Published in: Respiratory Research 1/2020

Open Access 01-12-2020 | COVID-19 | Research

Epidemiological characteristics and the entire evolution of coronavirus disease 2019 in Wuhan, China

Authors: Dongming Wang, Jing Cai, Tingming Shi, Yang Xiao, Xiaobing Feng, Meng Yang, Wenzhen Li, Wei Liu, Linling Yu, Zi Ye, Tao Xu, Jixuan Ma, Mingyan Li, Weihong Chen

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Background

Coronavirus Disease 2019 (COVID-19) spread rapidly around the world. We aimed to describe the epidemiological characteristics and the entire evolution of COVID-19 in Wuhan, and to evaluate the effect of non-pharmaceutical intervention by the government.

Methods

The information of COVID-19 cases until Mar 18, 2020 in Wuhan were collected from the national infectious disease surveillance system in Hubei province.

Results

A total of 49,973 confirmed cases were reported until Mar 18, 2020 in Wuhan. Among whom, 2496 cases died and the overall mortality was 5.0%. Most confirmed cases (25,619, 51.3%) occurred during Jan 23 to Feb 4, with a spike on Feb 1 (new cases, 3374). The number of daily new cases started to decrease steadily on Feb 19 (new cases, 301) and decreased greatly on Mar 1 (new cases, 57). However, the mortality and the proportion of severe and critical cases has been decreasing over time, with the lowest of 2.0 and 10.1% during Feb 16 to Mar 18, 2020, respectively. The percentage of severe and critical cases among all cases was 19.6%, and the percentage of critical and dead cases aged over 60 was 70.1 and 82.0%, respectively.

Conclusion

The number of new cases has dropped significantly after the government taking the isolation of four types of personnel and the community containment for 14 days. Our results indicate that the mortality and proportion of severe and critical cases gradually decreased over time, and critical and dead cases are more incline to be older individuals.
Appendix
Available only for authorised users
Literature
3.
go back to reference Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.CrossRef Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.CrossRef
5.
go back to reference Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207.CrossRef Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207.CrossRef
7.
go back to reference Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis. 2020;221(11):1757–61.CrossRef Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis. 2020;221(11):1757–61.CrossRef
8.
go back to reference Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al: Clinical features of patients infected with 2019 Novel coronavirus in Wuhan, China. Lancet (London, Engl) 2020, 395(10223):497–506. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al: Clinical features of patients infected with 2019 Novel coronavirus in Wuhan, China. Lancet (London, Engl) 2020, 395(10223):497–506.
9.
go back to reference Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China challenges for Global Health governance. JAMA. 2020;323(8):709–10.CrossRef Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China challenges for Global Health governance. JAMA. 2020;323(8):709–10.CrossRef
10.
go back to reference Nkengasong J. China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response. Nat Med. 2020;26(3):310–1.CrossRef Nkengasong J. China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response. Nat Med. 2020;26(3):310–1.CrossRef
11.
go back to reference Kickbusch I, Leung G. Response to the emerging novel coronavirus outbreak. BMJ. 2020;368:m406.CrossRef Kickbusch I, Leung G. Response to the emerging novel coronavirus outbreak. BMJ. 2020;368:m406.CrossRef
12.
go back to reference Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–41.CrossRef Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–41.CrossRef
14.
go back to reference Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet (London, Engl). 2020;395(10225):689–97.CrossRef Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet (London, Engl). 2020;395(10225):689–97.CrossRef
15.
go back to reference Chen X, Yu B. First two months of the 2019 coronavirus disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model. Glob Health Res Policy. 2020;5:7.CrossRef Chen X, Yu B. First two months of the 2019 coronavirus disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model. Glob Health Res Policy. 2020;5:7.CrossRef
17.
go back to reference Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.CrossRef Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.CrossRef
18.
go back to reference Wang D, Zhou M, Nie X, Qiu W, Yang M, Wang X, Xu T, Ye Z, Feng X, Xiao Y, et al. Epidemiological characteristics and transmission model of Corona virus disease 2019 in China. J Infect. 2020;80(5):e25–7.CrossRef Wang D, Zhou M, Nie X, Qiu W, Yang M, Wang X, Xu T, Ye Z, Feng X, Xiao Y, et al. Epidemiological characteristics and transmission model of Corona virus disease 2019 in China. J Infect. 2020;80(5):e25–7.CrossRef
19.
go back to reference Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.CrossRef Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.CrossRef
20.
go back to reference Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–82.CrossRef Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–82.CrossRef
21.
go back to reference de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–34.CrossRef de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–34.CrossRef
22.
go back to reference Wong G, Liu W, Liu Y, Zhou B, Bi Y, Gao GF. MERS, SARS, and Ebola: the role of super-spreaders in infectious disease. Cell Host Microbe. 2015;18(4):398–401.CrossRef Wong G, Liu W, Liu Y, Zhou B, Bi Y, Gao GF. MERS, SARS, and Ebola: the role of super-spreaders in infectious disease. Cell Host Microbe. 2015;18(4):398–401.CrossRef
23.
go back to reference Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. Jama. 2020;323(16):1612–4.CrossRef Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. Jama. 2020;323(16):1612–4.CrossRef
Metadata
Title
Epidemiological characteristics and the entire evolution of coronavirus disease 2019 in Wuhan, China
Authors
Dongming Wang
Jing Cai
Tingming Shi
Yang Xiao
Xiaobing Feng
Meng Yang
Wenzhen Li
Wei Liu
Linling Yu
Zi Ye
Tao Xu
Jixuan Ma
Mingyan Li
Weihong Chen
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
COVID-19
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-01525-7

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.